Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer

Status Active, not recruiting

Clinical Trial Summary

Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years.

Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive bladder cancer (MIBC).

Guidelines do not recommend FDG-Positron Emission Tomography (PET) Computed Tomography (CT), but rather CT for lymph node and metastatic staging, despite its low accuracy. We performed a retrospective analysis of patients undergoing PET CT for localized MIBC in two centers, to help define the utility of PET CT in this setting.

Clinical Trial Description

Background:

Bladder cancer is the second most frequent genito-urinary cancer, and the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Curative treatment of muscle invasive urothelial carcinoma localized to the bladder includes cisplatin-based neoadjuvant chemotherapy, followed by radical cystectomy with lymph nodes dissection. Nonetheless, surgery indications depend on pre-operative staging regarding nodes and metastatic involvement.

Computed Tomography (CT) scan is the reference imaging study for loco-regional and metastatic staging. Lymph node involvement evaluation is based on morphologic criteria only. Its sensitivity lies between 30 and 53% and its specificity between 67 and 91%. Yet, optimal node staging is crucial for therapeutic decision.

FDG-Positron Emission Tomography (PET) CT, using both morphologic and functional criteria, could help for node staging in muscle invasive bladder cancer assessment, especially by detecting infracentimetric involved lymph nodes. Moreover, it could be useful for detecting distant metastasis.

Objective:

To evaluate the accuracy of the PET CT for lymph node staging and to determine the rate of treatment modification according to PET CT results

Methods:

Retrospective study based on the medical records of every patient undergoing a PET CT at the time of diagnosis of MIBC from 01/2005 to 12/2017 in Bordeaux (Bergonie Institute and University Hospital). PET CT could have been done before any treatment (PET 1) and/or after neo-adjuvant chemotherapy and before surgery (PET 2). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04053101
Study type	Observational
Source	Institut Bergonié
Contact
Status	Active, not recruiting
Phase
Start date	April 1, 2017
Completion date	August 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101812` - Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer	Phase 2
Active, not recruiting	`NCT02546661` - Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	Phase 1
Active, not recruiting	`NCT03732677` - Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	Phase 3
Terminated	`NCT02716896` - Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer	N/A
Recruiting	`NCT04047693` - Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma	Phase 2
Recruiting	`NCT02648100` - Basal Like Bladder Cancer : Signature and Therapeutic	N/A
Terminated	`NCT03397394` - Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma	Phase 2
Recruiting	`NCT05236218` - To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
Active, not recruiting	`NCT04730219` - Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma	Phase 2
Completed	`NCT03294304` - BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy	Phase 2
Completed	`NCT03773666` - A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)	Phase 1
Completed	`NCT01031420` - Dose Dense MVAC for Muscle Invasive Bladder Cancer	Phase 2
Recruiting	`NCT04813107` - A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT03747419` - Avelumab and Radiation in Muscle-Invasive Bladder Cancer	Phase 2
Recruiting	`NCT04960709` - Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin	Phase 3
Not yet recruiting	`NCT05860543` - Clinical Performance Evaluation of the C2i Test
Recruiting	`NCT05979740` - RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer — TEP Vessie

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms